Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Andrologia ; 47(4): 433-7, 2015 May.
Artigo em Inglês | MEDLINE | ID: mdl-24773173

RESUMO

Androgens are essential for the development and growth of the genitalia. They regulate the erectile physiology by multiple mechanisms. Several studies have examined associations among sex hormones' serum levels, erectile function and sex drive. We sought to identify a protocol for using testosterone in men with erectile dysfunction and late-onset hypogonadism (LOH). During a 16-month period, men with erectile dysfunction who presented to the andrology clinic were selected. They underwent a complete physical examination and filled out the International Index of Erectile Function-5 questionnaire. Serum luteinising hormone (LH) and testosterone levels were evaluated. Patients received a single intramuscular injection of 250 mg testosterone. Thereafter, serum levels of LH and testosterone were measured 3 weeks later. The mean age was 53 years old. After treating patients with testosterone, 45 (94%) showed improvement in LOH symptoms including libido, loss of energy, irritability and quality of life. The mean International Index of Erectile Function was 9 and 13.1, prior to and after treatment respectively. Mean serum testosterone levels before and after treatment were 4.2 and 4.1 ng ml(-1) respectively (P = 0.849). Mean serum LH revealed a significant decrease after the study (P = 0.004) (6.12 and 5.1 ng ml(-1) , before and after the study respectively). Our findings suggested that testosterone replacement therapy improves libido and LOH symptoms in individuals with almost normal or lower limit normal value of serum testosterone levels.


Assuntos
Disfunção Erétil/diagnóstico , Terapia de Reposição Hormonal , Hipogonadismo/diagnóstico , Hormônio Luteinizante/sangue , Testosterona/sangue , Adulto , Disfunção Erétil/sangue , Disfunção Erétil/tratamento farmacológico , Humanos , Hipogonadismo/sangue , Hipogonadismo/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Satisfação do Paciente , Qualidade de Vida , Testosterona/uso terapêutico
2.
Int J Organ Transplant Med ; 3(2): 79-84, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-25013627

RESUMO

BACKGROUND: Wound healing disorders are probably the most common post-transplantation surgical complications. It is thought that wound healing disturbance occurs due to antiproliferative effects of immunosuppressive drugs. On the other hand, success of transplantation is dependent on immunosuppressive therapies. Antihuman thymocyte globulin (ATG) has been widely used as induction therapy but the impact of this treatment on wound healing is not fully understood. OBJECTIVE: To investigate wound healing complications after ATG therapy in renal transplant recipients. METHODS: The medical records of 333 kidney transplant recipients were assessed for wound healing disorders. Among these patients, 92 received ATG and 5 doses of 1.5 mg/kg ATG along with the standard protocol of drugs. RESULTS: The mean age of patients was 38.9 years. Of 333 recipients, 92 (23.7%) received ATG; 21 (6.3%) developed wound healing complications. There was a significant relationship between ATG therapy and wound complications (p=0.034). Also, women were more likely to develop wound healing disorders than men (p=0.002). No statistical difference was observed between age and wound healing complication (p=0.28). There was no significant difference between the mean duration of hospitalization between ATG and Non-ATG group (p=0.9). CONCLUSION: ATG increases the risk of overall wound complications. It is needed to pay more attention to the patients treated with this immunosuppressant to avoid the risk of re-interventions, lessen the duration of hospitalization and decrease the impairment of graft function.

3.
Int J Gynaecol Obstet ; 15(5): 390-5, 1978.
Artigo em Inglês | MEDLINE | ID: mdl-28969

RESUMO

A statistical review of 113 cases of hydatidiform mole (HM) seen at Pahlavi University Hospital from January 1970 to December 1975 is presented. The incidence of the disease was found to be 1:314 pregnancies. In this study, 73.5% of the patients presumably had acceptable socioeconomic circumstances. The highest incidence of the disease was found in patients 15-25 years old, and it increased with parity. All patients presented with a period of amenorrhea and vaginal spotting. More than 50% of the patients sought treatment after 1-2 weeks of uterine bleeding. Signs and symptoms of the disease are discussed. The management of patients with HM and coexisting difficulties are presented.


Assuntos
Mola Hidatiforme Invasiva/epidemiologia , Mola Hidatiforme/epidemiologia , Neoplasias Uterinas/epidemiologia , Adolescente , Adulto , Coriocarcinoma/diagnóstico , Coriocarcinoma/epidemiologia , Coriocarcinoma/terapia , Feminino , Seguimentos , Humanos , Mola Hidatiforme/diagnóstico , Mola Hidatiforme/terapia , Mola Hidatiforme Invasiva/diagnóstico , Mola Hidatiforme Invasiva/terapia , Irã (Geográfico) , Pessoa de Meia-Idade , Paridade , Gravidez , Fatores Socioeconômicos , Neoplasias Uterinas/diagnóstico , Neoplasias Uterinas/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...